(Q46623182)

23 December 2017

title

Statins restore ischemic limb blood flow in diabetic microangiopathy via eNOS/NO upregulation but not via PDGF-BB expression (English)

1 reference

23 December 2017

author name string

Takaaki Fujii

1

1 reference

23 December 2017

Mitsuho Onimaru

2

1 reference

23 December 2017

Yoshikazu Yonemitsu

3

1 reference

23 December 2017

Hiroyuki Kuwano

4

1 reference

23 December 2017

Katsuo Sueishi

5

1 reference

23 December 2017

publication date

25 April 2008

1 reference

23 December 2017

American Journal of Physiology Heart and Circulatory Physiology

published in

1 reference

23 December 2017

volume

294

1 reference

23 December 2017

issue

6

1 reference

23 December 2017

page(s)

H2785-91

1 reference

23 December 2017

Enhancement of ischemia-induced angiogenesis by eNOS overexpression

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00149.2008

HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00149.2008

Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00149.2008

Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00149.2008

Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00149.2008

Beneficial cardiovascular pleiotropic effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00149.2008

HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00149.2008

Nonendothelial mesenchymal cell-derived MCP-1 is required for FGF-2-mediated therapeutic neovascularization: critical role of the inflammatory/arteriogenic pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00149.2008

VEGF function for upregulation of endogenous PlGF expression during FGF-2-mediated therapeutic angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00149.2008

Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00149.2008

Mechanisms underlying endothelial dysfunction in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00149.2008

The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00149.2008

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00149.2008

Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00149.2008

Nitric oxide synthase modulates angiogenesis in response to tissue ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00149.2008

Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00149.2008

Rho GTPases, statins, and nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00149.2008

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00149.2008

Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00149.2008

Hyperglycaemia-induced superoxide production decreases eNOS expression via AP-1 activation in aortic endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00149.2008

The lower the better? Reviewing the evidence for more aggressive cholesterol reduction and goal attainment

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00149.2008

Essential role of PDGFRalpha-p70S6K signaling in mesenchymal cells during therapeutic and tumor angiogenesis in vivo: role of PDGFRalpha during angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00149.2008

Endothelium-dependent effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00149.2008

10.1152/AJPHEART.00149.2008

21 January 2018

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017